Filing Flows › Cytokinetics (CYTK) › Q2 2026
Cytokinetics (CYTK) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 6, 2026
Cytokinetics (CYTK) reported revenue of $28.6M for the second quarter 2026 (Q2 2026), -57% from a year earlier and +48% from the quarter before. Operating margin was -626.0%, net loss $199M (694.4% of revenue).
Cytokinetics, Q2 2026: revenue $28.6M (-57% year over year), operating margin -626.0%, net loss $199M, operating cash flow −$160M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $28.6M | +48% | -57% |
| Operating profit | −$179M | — | — |
| Net earnings | −$199M | — | — |
| Operating cash flow | −$160M | — | — |
What changed
Revenue was $28.6M in Q2 2026, down 57% year over year and up 48% from the previous quarter. Net Product Revenue was the largest line at 89% of revenue.
Operating costs exceeded revenue by $179.2M, an operating margin of -626.0%. Total costs grew 17% against a revenue fall of 57%. The fastest-growing cost line was Other operating costs (+131%). The quarter ended with a net loss of $198.8M, narrower than the previous quarter's $206.0M loss.
Operating cash flow was −$159.8M. Non-cash charges added back $3.6M of depreciation and amortization and $35.7M of share-based compensation. Capital expenditures of $4.3M exceeded it, leaving free cash flow of −$164.2M.
Questions
What was Cytokinetics' revenue in the second quarter 2026?
Cytokinetics (CYTK) reported revenue of $28.6M for the second quarter 2026 (Q2 2026), -57% from a year earlier and +48% from the quarter before.
Was Cytokinetics profitable in the second quarter 2026?
Operating loss was $179M (-626.0% of revenue) and net loss $199M.
Source: Cytokinetics 10-Q on SEC EDGAR.